A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Mild to Moderate Psoriasis Clinical Trial

Official title:
A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis

Status Completed

Clinical Trial Summary

To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02529956
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 1
Start date	November 2012
Completion date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03222622` - Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis	Phase 2
Withdrawn	`NCT00788424` - Topical Application of AS101 for the Treatment of Psoriasis	Phase 2
Completed	`NCT01587755` - Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)	Phase 4
Recruiting	`NCT05249972` - A Phase III Study in Subjects With Mild to Moderate Psoriasis.	Phase 3
Recruiting	`NCT05965089` - A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.	Phase 1
Completed	`NCT01000714` - Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis	Phase 2